Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats

Pharmacology

Volumn 77, Issue 1, 2006, Pages 25-32

  Trivedi, Chitrang J ^a   Balaraman, R ^a   Majithiya, Jayesh B ^a   Bothara, Sunil B ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Atorvastatin; Isoproterenol induced myocardial infarction; Myocardial infarction

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CHOLINE ACETYLTRANSFERASE; CREATINE KINASE; GLUTATHIONE; ISOPRENALINE; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART HYPERTROPHY; HEART INFARCTION; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BODY WEIGHT; CATALASE; GLUTATHIONE; HEART; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOPROTERENOL; LIPID PEROXIDATION; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; ORGAN SIZE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 33646507678     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092308     Document Type: Article

References (49)

1. McCord JM: Oxygen-derived free radicals in post ischemic tissue injury. N Engl J Med 1985;312:159-163.
2. Neelam S, Arvindar KD, Charita S, Pawan KS: Oxidative stress and heart failure. Mol Cell Biochem 1995;47:77-81.
3. Karthikeyan K, Saralabai BR, Gauthaman K, Sathish KS, Devaraj NS: Cardioprotective effect of the alcoholic extract of Terminalia arjuna bark in an in vivo model of myocardial ischemic reperfusion injury. Life Sci 2003;73:2727-2739.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis B, Rand BE: The Cholesterol and Recurrent Events Trial Investigators. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
5. Jones SP, Trocha SD, Lefer DJ: Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vase Biol 2001;21:2059-2064.
6. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;28:23-30.
7. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-184.
8. Leung WH, Lau CP, Wong CK: Beneficial effect on cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
9. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M: Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 2003;17:25-30.
10. Di Napoli P, Antonio TA, Grilli A, Spina R, Felaco M, Barsotti A, De Caterina R: Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001;51:283-293.
11. Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, MacMahon S, Shaw J, Simes RJ, Thompson PL, White HD, Hunt D: Effects of pravastatin in 3,260 patients with unstable angina: results from the LIPID study. Lancet 2000;356:1871-1875.
12. Sharma M, Kishore K, Gupta SK, Joshi S, Arya DS: Cardioprotective potential of Ocimum sanctum in isoproterenol-induced myocardial infarction in rats. Mol Cell Biochem 2001;225:75-83.
13. Bafna PA, Balaraman R: Anti-ulcer and antioxidant activity of DHC-1, a herbal formulation. J Ethnopharmacol 2004;90:123-127.
14. Mishra HP, Fridovich I: The role of superoxide anion in the auto-oxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170-3175.
15. Aebi H: Oxidoreductases acting on groups other than CHOH: Catalase; in Colowick SP, Kaplan NO, Packer L (eds): Methods in Enzymology, vol 105. London, Academic Press, 1984, pp 121-125.
16. Moron MS, Depierre JW, Mannervik B: Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582:67-78.
17. Slater TF, Sawyer BC: The stimulatory effects of carbon tetrachloride and other halogenoalkanes or peroxidative reactions in rat liver fractions in vitro. Biochem J 1971;123:805-814.
18. Bonting SL: Sodium-potassium activated adenosine triphosphate and cation transport. New York, Willey Interscience, 1970, pp 257-263.
19. 2+-ATPase from erythrocyte membrane. Biochem Biophys Acta 1983;728:281-288.
20. 2+-ATPase activity in normal, regenerating and malignant cells. Biochem Biophys Acta 1982;684:67-74.
21. Mohan P, Bloom S: Lipolysis is an important determinant of isoproterenol-induced myocardial necrosis. Cardiovasc Pathol 1999;8:255-261.
22. Ferrans VJ, Hibbs RG, Walsh JJ, Burch GE: Histochemical and electron microscopical studies on the cardiac necrosis produced by sympathomimetic agents. Ann NY Acad Sci 1969;156:309-332.
23. Balaz T, Bloom S: Cardiotoxicity of adrenergic bronchodilator and vasodilating antihypertensive drugs; in Van Stee (ed): Cardiovascular Toxicology. New York, Raven Press, 1982, pp 199-220.
24. Rockhold RW: Cardiotoxicity of naturally occurring catecholamines; in Baskin SI (ed): Principles of Cardiac Toxicology. Boca Raton, CRC Press, 1991, pp 347-417.
25. Bloom S, Davis DL: Calcium as mediator of isoproterenol-induced myocardial necrosis. Am J Pathol 1972;69:459-470.
26. Dhalla KS, Rupp H, Beamish RE, Dhalla NS: Mechanisms of alterations in cardiac membrane calcium transport due to excess catecholamines. Cardiovas Drugs Ther 1996;10:231-238.
27. Rathore N, Kale M, John S, Bhatnagar D: Lipid peroxidation and antioxidant enzymes in isoproterenol-induced oxidative stress in rat erythrocyte. Ind J Physiol Pharmacol 2000;44:161-166.
28. Bors W, Michael C, Saran M, Lengfelder E: The involvement of oxygen radicals during the auto oxidation of adrenaline. Biochim Biophys Acta 1978;540:162-172.
29. Dhalla NS, Yates JC, Lee SL, Singh A: Functional and subcellular changes in the isolated rat heart perfused with oxidised isoproterenol. J Mol Cell Cardiol 1978;10:31-41.
30. Zhanga GX, Kimuraa S, Nishiyamaa A, Shokojia T, Rahmana M, Yaoa L, Nagaib Y, Fujisawab Y, Miyatakeb A, Abe Y: Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005;65:230-238.
31. Karthikeyan K, Saralabai BR, Gauthaman K, Devaraj NS: Protective effect of propyl gallate against myocardial oxidative stress-induced injury in rat. J Pharm Pharmacol 2005;57:67-73.
32. Kombrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW: Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989;248:498-505.
33. Satoh K, Ichihara K: Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur J Pharmacol 1995;292:271-275.
34. Satoh K, Nakai T, Ichihara K: Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia. Eur J Pharmacol 1994;270:365-369.
35. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
36. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-305.
37. Wagner TK, Andreas H, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2000;20:61-69.
38. Franzoni F, Galvan A, Regoli F, Ferrannini E, Galetta F: A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-321.
39. Parker RA, Huang Q, Tesfamariam B: Influence of 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 2003;169:19-29.
40. +-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol 1992;262:C664-C671.
41. Sood S, Narang D, Dinda AK, Maulik SK: Chronic oral administration of Ocimum sanctum Linn. augments cardiac endogenous antioxidants and prevents isoproterenol-induced myocardial necrosis in rats. J Pharm Pharmacol 2005;57:127-133.
42. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T: An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem Pharm Bull 1999;47:1010-1012.
43. Portman MA, Zhang J: Myocardial energy transport and heart failure. Current Cardiol Rev 2005;1:17-27.
44. Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, Kobara M, Asayama J, Nakagawa M: Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circ 1999;99:817-822.
45. Ithayarasi AP, Shyamala Devi CS: Effect of α-tocopherol on isoproterenol-induced changes in lipid and lipoprotein profile in rats. Ind J Pharmacol 1997;29:399-404.
46. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF: Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005;65:296-298.
47. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-1135.
48. Laufs U, Fata VL, Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-31729.
49. Jones SP, Bolli R: The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23.